4-benzoyl-5-(4-bromophenyl)-1-(pyridin-3-ylmethyl)-3-isopropoxy-1H-pyrrol-2(5H)-one | 1610599-83-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 4-benzoyl-5-(4-bromophenyl)-1-(pyridin-3-ylmethyl)-3-isopropoxy-1H-pyrrol-2(5H)-one
• 英文别名: 3-benzoyl-2-(4-bromophenyl)-4-propan-2-yloxy-1-(pyridin-3-ylmethyl)-2H-pyrrol-5-one
• CAS: 1610599-83-1
• 化学式: C₂₆H₂₃BrN₂O₃
• 分子量: 491.384
• InChiKey: SSZOKBDMSNYVDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-Butenoic acid, 2-hydroxy-4-oxo-4-phenyl-, methyl ester, (2Z)- 在 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 24.17h， 生成 4-benzoyl-5-(4-bromophenyl)-1-(pyridin-3-ylmethyl)-3-isopropoxy-1H-pyrrol-2(5H)-one
  参考文献：
  名称：

  Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy

  摘要：

  Introducing an aryl moiety to our previous pyrrolidone scaffold by molecule fusing strategy afforded two sets of isopropylether-pyrrolidone and alpha-phenylethylamine-pyrrolidone derivatives. Two novel compounds 8b and 8g of the latter serial showed potent p53-MDM2 inhibitory activities with K-i values of 90 nM which were three-time higher than that of the parent compound. We also confirmed compound 8b can activate p53 proteins in lung cancer A549 cells. The results offered us valuable information for further lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.063

文献信息

• Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy
  作者：Jin Li、Yuelin Wu、Zizhao Guo、Chunlin Zhuang、Jianzhong Yao、Guoqiang Dong、Zhiliang Yu、Xiao Min、Shengzheng Wang、Yang Liu、Shanchao Wu、Shiping Zhu、Chunquan Sheng、Zhenyuan Miao、Wannian Zhang

  DOI：10.1016/j.bmcl.2014.04.063

  日期：2014.6

  Introducing an aryl moiety to our previous pyrrolidone scaffold by molecule fusing strategy afforded two sets of isopropylether-pyrrolidone and alpha-phenylethylamine-pyrrolidone derivatives. Two novel compounds 8b and 8g of the latter serial showed potent p53-MDM2 inhibitory activities with K-i values of 90 nM which were three-time higher than that of the parent compound. We also confirmed compound 8b can activate p53 proteins in lung cancer A549 cells. The results offered us valuable information for further lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.